Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
The company is seeking approval for a combination regimen of Itovebi with Pfizer 's PFE Ibrance (palbociclib) and AstraZeneca 's AZN Faslodex (fulvestrant). The intended treatment population includes adult patients with PIK3CA - mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. PFE's Ibrance and AZN's Faslodex are both currently approved for breast cancer treatment.
Please note that Roche's Itovebi, in combination with Pfizer's Ibrance and AstraZeneca's Faslodex, is currently approved for the same indication as above in several geographies, including the United States, with additional applications under review by other regulatory authorities worldwide.
Year to date, shares of RHHBY have surged 13.7% against the industry 's decline of 5.7%.
More on the Positive CHMP Opinion for RHHBY's Itovebi Therapy
The favorable CHMP opinion is supported by findings from Roche's phase III INAVO120 study, which demonstrated a 57% reduction in the risk of disease progression or death (progression-free survival) for patients receiving the Itovebi-based regimen compared with those treated with Pfizer's Ibrance and AstraZeneca's Faslodex alone in the first-line setting. This benefit was consistent across all pre-specified subgroups, including patients with more aggressive disease that had spread to three or more locations. Additionally, the regimen was well tolerated, with no new safety concerns identified.
In January 2025, positive top-line results from the final overall survival (OS) analysis of the INAVO120 study were announced, confirming a statistically significant and clinically meaningful survival advantage with the Itovebi-based treatment. Although OS data were still maturing at the time of the primary analysis, a clear favorable trend had already emerged. Full OS results are expected to be presented during an oral session at the 2025 American Society of Clinical Oncology Annual Meeting.
Per Roche, PIK3CA mutations, which occur in roughly 40% of HR-positive breast cancers, are associated with more aggressive disease and poorer survival outcomes. This highlights the critical need for early PIK3CA mutation testing before initiating first-line treatment, enabling timely access to effective PI3K-targeted therapies for patients with a less favorable prognosis. The Itovebi-based regimen could redefine the standard of care in this first-line setting, where current treatment options remain limited, pending approval.
Apart from the INAVO120 study, Roche is simultaneously evaluating various other combinations of Itovebi in three late-stage studies for treating PIK3CA-mutated, locally advanced or metastatic breast cancer. RHHBY is also planning further clinical investigations in breast cancer and other tumor types, aiming to extend the potential benefits of this targeted therapy to a broader population of patients with PIK3CA mutations.
RHHBY's Zacks Rank & Stock to Consider
Roche currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Bayer BAYRY, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Bayer's earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 43.4%.
BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.0% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
NBIS Q2 Earnings Coming Up: How Should You Play the Stock?
Nebius Group N.V. NBIS will report its second-quarter 2025 results on Aug. 7, before market open. The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter stands at a loss of 42 cents. The estimate has remained unchanged in the past 30 days. The consensus estimate for total revenues is pinned at $95.05 million. Based in Amsterdam, Nebius is positioning itself as a specialized AI infrastructure company. Its core operation is Nebius, which is an AI-powered cloud platform designed for intensive AI and ML workloads in both owned and colocation data center capacity. It resumed trading as a public company in October 2024. What Our Model Predicts for NBIS' Q2 Our proven model does not conclusively predict an earnings beat for NBIS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. But that is not the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. NBIS has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Factors to Focus on Ahead of NBIS' Q2 Earnings Accelerating demand for its AI infrastructure services is likely to have driven the top-line performance in the to be reported quarter. On the last earnings call, NBIS had highlighted that annualized recurring revenues or ARR for April were $310, providing a strong start for the second quarter. Due to strong April ARR, Nebius was confident in achieving its full-year ARR guidance of $750 million to $1 billion for 2025. Nebius is focused on boosting its data center footprint and its GPU deployments as part of its strategy to ramp up installed capacity across the United States and Europe. Establishing facilities in the United States means lower latency while serving domestic clients and boosting the advantages of the AI-native cloud. It added three new regions, including a strategic data center in Israel, in the last reported quarter. Collaboration with Saturn Cloud and deeper NVIDIA (NVDA) integration bodes well. It announced the general availability of NVIDIA GB200 Grace Blackwell Superchip capacity for its customers in Europe in June 2025. In the first quarter, Nebius significantly upgraded its AI cloud infrastructure through improvements to its Slurm-based cluster. Nebius is making substantial investments in improving its object storage capabilities, and the upgraded storage system ensures that big data sets can be easily accessed and saved quickly during model training, directly lowering time-to-result for end users. Nebius expanded integrations with external AI platforms like Metaflow, D Stack and SkyPilot, enabling customers to migrate tools with nominal friction. These factors are likely to have contributed to gaining more clients in the to be reported. Nonetheless, the intense competition from behemoths remains a concern, along with profitability issues. Nebius is a relatively new entrant in the AI cloud infrastructure space, which boasts behemoths like Amazon AMZN and Microsoft MSFT, and other upcoming players like CoreWeave CRWV. Amazon Web Services and Microsoft's Azure cloud platform together dominate more than half of the cloud services market. Nebius Group N.V. Price and EPS Surprise Nebius Group N.V. price-eps-surprise | Nebius Group N.V. Quote Despite its exceptional top-line growth, NBIS remains unprofitable, with management reaffirming that adjusted EBITDA will be negative for the full year 2025. Though it added that adjusted EBITDA will turn positive at 'some point in the second half of 2025.' NBIS has also raised its 2025 capital expenditure forecast to approximately $2 billion from the previous estimate of $1.5 billion, primarily due to some planned fourth-quarter spending shifting into the early first quarter. Higher capex can be a concern if revenues do not keep up the required pace to sustain such high capital intensity. Moreover, NBIS also highlighted that it will be deconsolidating Toloka as its voting share dropped below 50% due to investments from Jeff Bezos and Mikail Parakhin. Since the transaction closed in May 2025, NBIS will update its financials and guidance, excluding Toloka in its second quarter earnings report. Analysts have significantly revised their earnings estimates downward for NBIS' bottom line over the past 60 days. NBIS Stock Performance Nebius shares have risen 59.6% over the past six months, outperforming the Zacks C omputer & Technology sector and the Zacks Internet Software Services industry's growth of 6.8% and 10.4%, respectively. The S&P 500 Composite has returned 2.5% over the same time frame. Price Performance Image Source: Zacks Investment Research The gain is better than its peers, like Microsoft (up 29.6%) and Amazon (down 10.4%). On the other hand, CoreWeave, which is another hypergrowth pure play AI infrastructure company, has registered gains of 165%. NBIS' Stretched Valuation NBIS stock is also not so cheap, as its Value Style Score of F suggests a stretched valuation at this moment. In terms of Price/Book, NBIS shares are trading at 4.04X, almost the same as the Internet Software Services industry's ratio of 4.03, but it could mean more risk than opportunity. What to Do With NBIS Stock Before Q2? Intense competition, ongoing profitability issues, and high capex pressure weigh on short-term prospects. The recent Toloka deconsolidation adds uncertainty to future guidance. Given these risks and limited near-term upside, investors could benefit from offloading NBIS ahead of the second quarter results. Investors looking to invest should wait for a better entry point. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Nebius Group N.V. (NBIS): Free Stock Analysis Report CoreWeave Inc. (CRWV): Free Stock Analysis Report
CTV News
2 hours ago
- CTV News
Aluminum can maker Ball Corp lifts annual profit forecast buoyed by strong global demand
Canned processed pumpkins move along a conveyor belt in the case and label area of a cannery in Morton, Ill. THE CANADIAN PRESS/AP, Seth Perlman Ball Corp raised its annual profit forecast on Tuesday, after beating second-quarter results, fueled by resilient demand for its aluminum cans in key markets of North America and Europe, sending its shares up two per cent in premarket trading. Ball witnessed a 4.1 per cent rise in global aluminum packaging shipments during the quarter, up from a 2.6 per cent rise in the prior three months. This was driven by demand from packaged food firms, as consumers opted for canned foods and beverages amid sticky inflation, prompting them to cook more at home. The company, serving clients like PepsiCo, Coca-Cola and Constellation Brands, increased beverage packaging sales in North and Central America to US$1.61 billion, from US$1.47 billion last year. The manufacturer of aluminum cups, bottles and aerosol cans now expects comparable 2025 earnings to grow between 12 and 15 per cent, up from a prior range of 11 to 14 per cent growth. However, tariffs on steel and aluminum have pushed up input costs for companies such as Ball. 'We continue to view the direct impact from announced tariffs as manageable and are actively working with our customers to mitigate the effects of volatility in aluminum premium prices,' the company said on Tuesday. Ball CEO Daniel Fisher said the company was tightly managing its costs as it expects potential geopolitical uncertainties and market volatility in the second half of the year. Excluding items, it earned a profit of 90 cents per share in the quarter, beating expectations of 87 cents per share, according to data compiled by LSEG. Its revenue jumped 7.8 per cent to US$3.34 billion, above estimates of US$3.12 billion. --- Reporting by Anshi Sancheti in Bengaluru; Editing by Vijay Kishore
Globe and Mail
2 hours ago
- Globe and Mail
If You'd Invested $1,000 in PFE 5 Years Ago, Here's How Much You'd Have Today
Key Points Pfizer's stock is down over 60% from its December 2021 peak (as of Aug. 1). A drop in COVID-19 vaccines and treatment has caused a drop in Pfizer's revenue. Pfizer's stock appears to be in bargain territory for long-term investors. 10 stocks we like better than Pfizer › Five years ago, the world was in the thick of the COVID-19 global pandemic, bringing Pfizer (NYSE: PFE) into the spotlight because of the role it played in developing the COVID-19 vaccine with its partner BioNTech. It was able to get U.S. Food and Drug Administration (FDA) approval for its COVID-19 vaccine on Dec. 11, 2020, and it was released on Dec. 14, 2020. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » From mid-2020 to late 2021, Pfizer's stock skyrocketed, but since hitting its peak, it has reversed course. Had you invested $1,000 into Pfizer's stock on Aug. 1, 2020, your investment would only be worth around $638 as of Aug. 1, 2025. Pfizer's dividend would've cushioned some of the blow, but an investment then would still be less than your initial investment, at $828. PFE data by YCharts Why has Pfizer's stock struggled the past few years? Much of Pfizer's stock price troubles since hitting its Dec. 21 peak come down to a decline in demand for its COVID-19 vaccine and treatments, anticipated patent expirations on drugs like Ibrance (breast cancer) and Eliquis (blood clots), and an underwhelming pipeline. All isn't lost with Pfizer's stock, however. At its current levels -- trading at 7.7 times forward earnings -- Pfizer seems to be flirting with bargain territory. I don't expect a quick turnaround, but this low valuation gives it more long-term upside than downside. It also helps that the stock's dividend yield sits above 7.3%, more than 5.5 times the S&P 500 average. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
